Back to News & Events

BARDA: Call for innovations to tackle COVID-19

BARDA is calling for biomedical innovations to tackle COVID-19 pandemic through two major solilications. EZ-BAA solicitations for funding up to $750K, and BAA (no funding limit).

Deadline for EZ-BAA submission is June 30th. Innovations  are sought for multiple areas (.e. molecular assays, point-of-care diagnostics, vaccines, therapeutics, manufacturing platform, devices, ventilators.) Innovators are encouraged to review the most updated proposal solicitations through the links below:

EZ BAA:  https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view
BARDA BAA:  https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

Innovators are also welcome to submit quick applications to this market research portal on COVID-19 which are frequently reviewed by an inter-agency task force committee, including CDC, HHS, and NIH:
https://www.medicalcountermeasures.gov/app/barda/coronavirus.aspx

If you have any questions regarding your technology and how to engage with BARDA, Please contact Phuong Nguyen at the Center for Biotechnology for help: phuong.t.nguyen@stonybrook.edu

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2824 [post_author] => 1 [post_date] => 2017-09-20 13:41:33 [post_date_gmt] => 2017-09-20 13:41:33 [post_content] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by Center for Biotechnology BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule treatment for Alzheimer’s disease (AD) over the next 3 years. The award will enable the preparation and testing of Avanti’s proprietary compounds derivatized from natural catechins, which inhibit DYRK1A, an enzyme that modulates tau phosphorylation. Working with NY Institute for Basic Research and the University of California San Diego (UCSD), the company hopes to attenuate and potentially reverse pathogenesis for Alzheimer’s disease and other neurodegenerative diseases. “This award marks a significant milestone for Avanti Biosciences and an important step for their research into a treatment for Alzheimer’s disease” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is thrilled to see another success for one of the emerging bioscience companies fueling our regional bioecosystem and we proudly support Dr. Araldi’s work as one of our BioEntrepreneurs-in-Residence.” Dr. Gian Luca Araldi, Founder and Chief Executive Officer of Avanti, stated, “We are delighted to have been granted this funding from the NIA as it underscores the great need for innovative, effective treatments for this disease, and recognizes the potential benefits that our compounds may provide for patients with AD. The continuous support of Center for Biotechnology and the BioEntrepreneur-in-Residence program has been critical force in the development of our technology and the company as whole.” More than five million people in the United States are living with Alzheimer’s disease, a progressive, irreversible, neurodegenerative disease that destroys memory and other cognitive abilities. It is the sixth leading cause of death in the United States and as the aging population in the country grows, the incidence rate is expected to rise dramatically. Learn more about Avanti Biosciences: avantibiosciences.com [post_title] => CFB BEIR Receives $1.9M SBIR Fast-Track [post_excerpt] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by CFB BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule Alzheimer’s disease (AD) over the next 3 years. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-beir-receives-1-9m-sbir-fast-track [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:39:07 [post_modified_gmt] => 2018-01-23 14:39:07 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2824 [menu_order] => 138 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3926 [post_author] => 4 [post_date] => 2022-09-15 15:47:15 [post_date_gmt] => 2022-09-15 15:47:15 [post_content] =>

Registrations are now OPEN for the BARDA sponsored FedTech Startup Studio program. Join us on September 19th, 2022 from 4:00 pm - 5:00 pm ET and be among the first to learn about our application process, program sponsors, and the exciting curriculum you will learn over the course of the program.

Interested in applying? Applications are live and registrations are limited:
https://www.eventbrite.com/e/fedtech-startup-studio-2022-launch-event-tickets-391311482177


[post_title] => FedTech Startup Studio Info Session [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fedtech-startup-studio-info-session [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:41:43 [post_modified_gmt] => 2023-07-10 16:41:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3926 [menu_order] => 20 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2894 [post_author] => 1 [post_date] => 2017-12-05 15:50:11 [post_date_gmt] => 2017-12-05 15:50:11 [post_content] => The L’Oréal USA For Women in Science fellowship program honors female scientists at a critical stage in their careers with grants of $60,000 each. Since 2003, we’ve awarded 70 postdoctoral women scientists over $3.5 million in grants. L’Oréal USA For Women in Science fellowship program is seeking five exceptional female scientists looking to advance their research and serve as role models for the next generation of girls in STEM. Applications for the 2018 L’Oréal USA For Women in Science program are now open and are due by February 2, 2018. Candidates are selected from a variety of fields including the life and physical/material sciences, technology (including computer science), engineering, and mathematics. Candidates must have completed their PhD and have started in their postdoctoral position by the application deadline. The application and more information about the L’Oréal USA For Women in Science program can be found at www.lorealusa.com/forwomeninscience.  [post_title] => L’Oréal USA For Women in Science Fellowship Program [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => loreal-usa-for-women-in-science-fellowship-program [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:38:40 [post_modified_gmt] => 2018-01-23 14:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2894 [menu_order] => 132 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

CFB BEIR Receives $1.9M SBIR Fast-Track

More Information

FedTech Startup Studio Info Session

More Information

L’Oréal USA For Women in Science Fellowship Program

More Information